EUnetHTA
EUnetHTA 21 released the assessment framework for high-risk medical devices and in-vitro-diagnostics
29
Aug 2022
On July 27, 2022, the EUnetHTA 21 released the assessment framework for high-risk medical devices (MDs) and in-vitro-diagnostics (IVDs). The objective of this deliverable is to define the framework for Joint Clinical Assessments of high-risk MDs and IVDs with a view to fostering national uptake of the Joint Clinical Assessments reports early in the life cycle of a single technology.
Read more
04
Oct 2021
On 17 September 2021, the European Health and Digital Executive Agency signed the Service Contract for the Provision of Joint Health Technology Assessment Work Supporting the Continuation of EU Cooperation on HTA. The contract has now been awarded to the EUnetHTA21 consortium, which comprises the following 13 organizations from the EUnetHTA. The project will start in September 2021 and will run for two years (until September 2023).
Read more
02
Sep 2021
At the beginning of August 2021, the European Network for Health Technology Assessment, EUnetHTA, released a final report on the surgical procedures for the treatment of obesity. The results suggest little or no difference in the effects of different bariatric surgery procedures on weight loss and diabetes control. However, the results are based mainly on low to very low certainty evidence, with few or even single studies providing data for many of the comparisons.
Read more
14
May 2021
In late April 2021, the European Network for Health Technology Assessment, EUnetHTA, in partnership with the Austrian Institute for HTA (AIHTA), released a final report on the comparative effectiveness of surgical techniques and devices for the treatment of benign prostatic hyperplasia. Twenty-one minimally invasive surgical treatments for benign prostatic hyperplasia were compared. Newer technologies may offer some advantage over transurethral resection of the prostate by reducing the transfusion requirement.
Read more
21
Jan 2021
The Austrian Institute for Health Technology Assessment (AIHTA) completed a research project, “Lung cancer screening in risk groups: Systematic reviews of effectiveness and utility (part 1) and costs and budgetary consequences (part 2),” and published the reports in the mid of December 2020.
Read more
24
Sep 2020
In August 2020, the network of European HTA agencies, EUnetHTA, announced the final plan of the project OTCA26 “Surgical procedures for treatment of obesity.” The key question of the assessment is bariatric surgery for the treatment of adults with obesity.
Read more
09
Sep 2020
At the end of July 2020, the network of European HTA agencies, EUnetHTA, announced the final plan of the project OTCA27 “Comparative effectiveness of surgical techniques and devices for the treatment of benign prostatic hyperplasia (BPH).”
Read more
28
Aug 2020
In July 2020, the network of European HTA agencies, EUnetHTA, announced a final project plan of the project OTCA25 “Stereotactic Body Radiation Therapy (SBRT) for lung, prostate, and liver cancer.”
Read more
07
Aug 2020
On July 03, 2020, the network of European HTA agencies, EUnetHTA, published the final report for the Rapid Relative Effectiveness Assessment OTCA24 ‘The 24-hour blood pressure measurement device Mobil-O- Graph® with the built-in algorithm ARCSolver® to measure arterial stiffness for the optimization of hypertension treatment.”
Read more
15
Jul 2020
On June 18, 2020, the network of European HTA agencies, EUnetHTA, published the final report for the rapid assessment OTCA21 "Hypoglossal Nerve Stimulation (HGNS) for treatment of obstructive sleep apnea."
Read more
05
Feb 2020
In late January 2020, the network of European HTA agencies, EUnetHTA, announced the final plan of the project OTCA21 “Hypoglossal nerve stimulation systems for treatment of obstructive sleep apnoea.”
Read more
23
Jan 2020
In early January 2020, the network of European HTA agencies, EUnetHTA, announced the final plan of the project OTCA24 “The 24-hour blood pressure measurement device Mobil-O-Graph® with the built-in pulse wave velocity algorithm ARCSolver® to measure arterial stiffness for the optimization of hypertension treatment and assessment of cardiovascular risk”.
Read more